Acute Pancreatitis Market

DelveInsight’s ‘Acute Pancreatitis (AP) – Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Acute Pancreatitis (AP), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Acute Pancreatitis (AP) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted AP symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current Acute Pancreatitis (AP) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Acute Pancreatitis (AP) Disease Understanding and Treatment Algorithm

Acute Pancreatitis (AP) Overview

Acute pancreatitis (AP) is an acute inflammatory disease of the pancreas that presents as severe upper abdominal pain, often accompanied by nausea and vomiting. In acute pancreatitis, which has numerous causes, inflammation of the pancreas occurs, which can lead to pancreatic cell death or necrosis and systemic inflammation, a precursor to organ failure. Normal pancreatic functions, such as the secretion of digestive enzymes required to break down food in the gut, are disabled.


It may range in severity from self-limiting, characterized by mild pancreatic edema, to severe systemic inflammation with pancreatic necrosis, organ failure and death. There are several clinical, laboratory, and radiologic risk factors and scoring systems that are used to predict severity of AP, but none is optimal.  Severe complications arise due to the acute inflammatory response that takes place in the pancreas. These complications can lead to systemic inflammatory response syndrome, or SIRS, in which the function of other tissues including the lung are compromised. Approximately one third of patients with severe acute pancreatitis develop acute lung injury or ARDS. Lung failure accounts for 60% of deaths associated with acute pancreatitis in developed countries.


Acute pancreatitis usually begins with gradual or sudden pain in the upper abdomen that sometimes extends to the back. The pain may be mild at first and become worse after eating. The pain is often severe, constant, and commonly lasts for several days in the absence of treatment. A person with acute pancreatitis usually looks and feels very ill and needs immediate medical attention. Most cases require hospitalization for 3 to 5 days for close monitoring, pain control, and intravenous hydration. Other symptoms can include: swollen and tender abdomen, nausea and vomiting, fever and rapid pulse.


The diagnosis of acute pancreatitis requires at least 2 of the following: typical upper abdominal pain, elevated levels of amylase or lipase, and confirmatory findings from cross-sectional imaging analysis. Although, the disease is usually confirmed by medical history, physical examination, and typically a blood test (amylase or lipase) for the pancreas' digestive enzymes. Blood amylase or lipase levels are typically elevated 3 times the normal level during acute pancreatitis. In some cases, when the blood tests are not elevated, and the diagnosis is still in question, abdominal imaging, such as a computed tomography (CT) scan, might be performed.


Acute Pancreatitis (AP) Diagnosis and Treatment

It covers the details of conventional and current medical therapies, and diagnosis available in the Acute Pancreatitis (AP) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.


The DelveInsight Acute Pancreatitis (AP) market report gives a thorough understanding of AP symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides AP symptoms of treatment algorithms and treatment guidelines for AP symptoms in the US, Europe, and Japan.

Acute Pancreatitis (AP) Epidemiology

The epidemiology division’s Acute Pancreatitis symptoms provides insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Acute Pancreatitis (AP) epidemiology segmented as the Diagnosed Incident Cases of Acute Pancreatitis (AP), Gender-specific cases of Acute Pancreatitis (AP), Diagnosed Incident Cases of Acute Pancreatitis (AP) by Etiology and Diagnosed Incident Cases of Acute Pancreatitis (AP) by Severity. The report includes the Incident scenario of AP symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.


Country Wise- Acute Pancreatitis (AP) Epidemiology

The epidemiology segment also provides the Acute Pancreatitis (AP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The total 7MM incident cases of Acute Pancreatitis (AP) were 495,516 in 2017.

Acute Pancreatitis (AP) Drug Chapters

The drug chapter segment of the Acute Pancreatitis (AP) report encloses the detailed analysis of AP drugs. It also helps understand the Acute Pancreatitis (AP) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


Acute Pancreatitis (AP) Emerging Drugs


CalciMedica’s lead product candidate, Auxora (formerly CM4620), a proprietary intravenous-formulated CRAC channel inhibitor, is being developed for several indications including the treatment of acute inflammatory diseases associated with dysregulation of intracellular calcium in organ tissues like the lung, pancreas or kidneys such as that of Acute Pancreatitis (AP).

Products detail in the report…

Acute Pancreatitis (AP) Market Outlook

The Acute Pancreatitis (AP) market outlook of the report helps build the detailed comprehension of the historic, current and forecasted Acute Pancreatitis (AP) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.


This segment gives a thorough detail of Acute Pancreatitis (AP) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, Acute Pancreatitis (AP) market in 7MM is expected to change in the study period 2017–2030.


Key Findings

This section includes a glimpse of the Acute Pancreatitis (AP) market in 7MM. The market size of AP in the seven major markets was found to be USD 698.68 million in 2017.


The United States Market Outlook

This section provides a total of Acute Pancreatitis (AP) market size and market size by therapies in the United States.


The United States accounts for the highest AP market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


Acute pancreatitis is one of the most frequent gastrointestinal cause of hospital admissions in the US where patients typically present with severe, continuous upper abdominal pain radiating to the back. There are several factors which have led to an increase in the incidence of AP such as increasing incidence of obesity which promotes gallstone formation along with the increased availability of and use of tests to measure serum levels of pancreatic enzymes, which detect milder cases of AP.


EU-5 Countries: Market Outlook

The total Acute Pancreatitis (AP) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total Acute Pancreatitis (AP) market size and market size by therapies in Japan are mentioned in this section.

Acute Pancreatitis (AP) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017–2030. The analysis covers Acute Pancreatitis (AP) market uptake by drugs; patient uptake by therapies; and drug sales.


This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Acute Pancreatitis (AP) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Acute Pancreatitis (AP) key players involved in developing targeted therapeutics.

Major players include Auxora (CalciMedica) being assessed as potential therapies to be available in the market in the coming future.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Acute Pancreatitis (AP) emerging therapies.

Reimbursement Scenario in Acute Pancreatitis (AP)

While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient’s claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do his or her best to make sure that the patient receives Social Security Disability benefits as quickly as possible and will help the patient avoid the lengthy disability appeal process

KOL- Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Acute Pancreatitis (AP) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or the Acute Pancreatitis (AP) market trend. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Acute Pancreatitis (AP) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Acute Pancreatitis (AP), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Acute Pancreatitis (AP) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Acute Pancreatitis (AP) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Acute Pancreatitis (AP) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute Pancreatitis (AP) market

Report Highlights

  • In the coming years, Acute Pancreatitis (AP) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Acute Pancreatitis (AP) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • ajor players are involved in developing therapies for AP. The launch of emerging therapies will significantly impact the Acute Pancreatitis (AP) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for AP.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Acute Pancreatitis (AP) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Acute Pancreatitis (AP) Pipeline Analysis
  • Acute Pancreatitis (AP) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Acute Pancreatitis (AP) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Acute Pancreatitis (AP) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Acute Pancreatitis (AP) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Acute Pancreatitis (AP) Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Acute Pancreatitis (AP) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017–2030)?
  • What are the market's key findings across 7MM and which country will have the largest Acute Pancreatitis (AP) market Size during the forecast period (2017–2030)?
  • At what CAGR, the Acute Pancreatitis (AP) market is expected to grow by 7MM during the forecast period (2017–2030)?
  • What would be the Acute Pancreatitis (AP) market outlook across the 7MM during the forecast period (2017–2030)?
  • What would be the Acute Pancreatitis (AP) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of the Acute Pancreatitis (AP)?
  • What is the historical Acute Pancreatitis (AP) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
  • What would be the forecasted patient pool of Acute Pancreatitis (AP) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Acute Pancreatitis (AP)?
  • Out of all 7MM countries, which country would have the highest incident population of Acute Pancreatitis (AP) during the forecast period (2017–2030)?
  • At what CAGR the population is expected to grow by 7MM during the forecast period (2017–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Acute Pancreatitis (AP)?
  • What are the current treatment guidelines for treating Acute Pancreatitis (AP) in the USA, Europe, and Japan?
  • What are the Acute Pancreatitis (AP) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Acute Pancreatitis (AP)?
  • How many therapies are developed by each company for the treatment of Acute Pancreatitis (AP)?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Acute Pancreatitis (AP)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Pancreatitis (AP) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Acute Pancreatitis (AP) and their status?
  • What are the key designations that have been granted for the emerging therapies for Acute Pancreatitis (AP)?
  • What are the global historical and forecasted market of Acute Pancreatitis (AP)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Acute Pancreatitis (AP) market
  • To understand the future market competition in the Acute Pancreatitis (AP) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Pancreatitis (AP) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Pancreatitis (AP) market
  • To understand the future market competition in the Acute Pancreatitis (AP) market

1. Key Insights

2. Executive Summary for Acute Pancreatitis

3. SWOT Analysis for Acute Pancreatitis

4. Acute pancreatitis Market Overview at a Glance

4.1. Market Share (%) Distribution of AP in 2017

4.2. Market Share (%) Distribution of AP in 2030

5. Disease Background and Overview

5.1. Introduction

5.2. Classification

5.3. Causes

5.4. Symptoms and Complications

5.5. Pathophysiology

5.6. Diagnosis

5.7. Biomarkers

6. Epidemiology and Patient Population

6.1. Key Findings

7. Total Diagnosed Incident Population of Acute Pancreatitis

8. Country Wise-Epidemiology of Acute Pancreatitis

8.1. The United States

8.1.1. Assumptions and Rationale

8.1.1.1. Total Diagnosed Incident Cases of AP in the United States

8.1.1.2. Diagnosed Incidence of AP by Etiology in the United States

8.1.1.3. Diagnosed Incidence of AP by Severity in the United States

8.1.1.4. Diagnosed Incidence of AP by Gender in the United States

8.1.1.5. Recurrent AP Cases in the United States

8.2. EU5 Countries

8.2.1. Germany

8.2.1.1. Total Diagnosed Incident Cases of AP in Germany

8.2.1.2. Diagnosed Incidence of AP by Etiology in Germany

8.2.1.3. Diagnosed Incidence of AP by Severity in Germany

8.2.1.4. Diagnosed Incidence of AP by Gender in Germany

8.2.1.5. Recurrent AP Cases in Germany

8.2.2. France

8.2.2.1. Total Diagnosed Incident Cases of AP in France

8.2.2.2. Diagnosed Incidence of AP by Etiology in France

8.2.2.3. Diagnosed Incidence of AP by Severity in France

8.2.2.4. Diagnosed Incidence of AP by Gender in France

8.2.2.5. Recurrent AP Cases in France

8.2.3. Italy

8.2.3.1. Total Diagnosed Incident Cases of AP in Italy

8.2.3.2. Diagnosed Incidence of AP by Etiology in Italy

8.2.3.3. Diagnosed Incidence of AP by Severity in Italy

8.2.3.4. Diagnosed Incidence of AP by Gender in Italy

8.2.3.5. Recurrent AP Cases in Italy

8.2.4. Spain

8.2.4.1. Total Diagnosed Incident Cases of AP in Spain

8.2.4.2. Diagnosed Incidence of AP by Etiology in Spain

8.2.4.3. Diagnosed Incidence of AP by Severity in Spain

8.2.4.4. Diagnosed Incidence of AP by Gender in Spain

8.2.4.5. Recurrent AP Cases in Spain

8.2.5. The United Kingdom

8.2.5.1. Total Diagnosed Incident Cases of AP in the UK

8.2.5.2. Diagnosed Incidence of AP by Etiology in the UK

8.2.5.3. Diagnosed Incidence of AP by Severity in the UK

8.2.5.4. Diagnosed Incidence of AP by Gender in the UK

8.2.5.5. Recurrent AP Cases in the UK

8.3. Japan

8.3.1. Assumptions and Rationale

8.3.2. Total Diagnosed Incident Cases of AP in Japan

8.3.3. Diagnosed Incidence of AP by Etiology in Japan

8.3.4. Diagnosed Incidence of AP by Severity in Japan

8.3.5. Diagnosed Incidence of AP by Gender in Japan

8.3.6. Recurrent AP Cases in Japan

9. Treatment and Management of Acute Pancreatitis

9.1. Japanese guidelines for the management of acute pancreatitis

9.2. American guidelines for the management of acute pancreatitis

9.3. Treatment Goals

9.4. Patient Journey for Acute Pancreatitis

10. Unmet Needs

11. Emerging Therapies

11.1. Auxora : CalciMedica, Inc.

11.1.1. Product Description

11.1.2. Other development activities

11.1.3. Clinical Development

11.1.3.1. Clinical Trials Information

12. Acute Pancreatitis: 7 Major Market Analysis

12.1. Key Findings

12.2. Total Market Size of Acute Pancreatitis in 7MM

13. Market Outlook by Country

13.1. Market Outlook

13.2. United States Market Size

13.2.1. Total Market Size of Acute Pancreatitis

13.2.2. Market Size of Acute Pancreatitis by Therapies

13.3. EU-5

13.3.1. Germany

13.3.1.1. Total Market size of Acute Pancreatitis

13.3.1.2. Market Size of Acute Pancreatitis by Therapies

13.3.2. France

13.3.2.1. Total Market size of Acute Pancreatitis

13.3.2.2. Market Size of Acute Pancreatitis by Therapies

13.3.3. Italy

13.3.3.1. Total Market size of Acute Pancreatitis

13.3.3.2. Market Size of Acute Pancreatitis by Therapies

13.3.4. Spain

13.3.4.1. Total Market size of Acute Pancreatitis

13.3.4.2. Market Size of Acute Pancreatitis by Therapies

13.3.5. United Kingdom

13.3.5.1. Total Market Size of Acute Pancreatitis

13.3.5.2. Market Size of Acute Pancreatitis by Therapies

13.4. Japan: Market Outlook

13.4.1. Total Market Size of Acute Pancreatitis

13.4.2. Market Size of Acute Pancreatitis by Therapies

14. Market Drivers

15. Market Barriers

16. Market access and Reimbursement

16.1. Access to Medicines for Acute Pancreatitis in US

16.2. Access to Medicines for Acute Pancreatitis in Europe

17. Appendix

17.1. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Table

Table 1: Summary of Acute Pancreatitis Market, Epidemiology, and Key Events (2017–2030)

Table 2: Definition of severity in Acute Pancreatitis

Table 3: Revised definitions of morphological features of Acute Pancreatitis

Table 4: Causes of Acute Pancreatitis

Table 5: Complications of Acute Pancreatitis

Table 6: Diagnosed Incident Population of Acute Pancreatitis in 7MM (2017-2030)

Table 7: Total Diagnosed Incident Cases of AP in the United States (2017-2030)

Table 8: Diagnosed Incidence of AP by Etiology in the United States (2017-2030)

Table 9: Diagnosed Incidence of AP by Severity in the United States (2017-2030)

Table 10: Diagnosed Incidence of AP by Gender in the United States (2017-2030)

Table 11: Recurrent AP Cases in the United States (2017-2030)

Table 12: Total Diagnosed Incident Cases of AP in Germany (2017-2030)

Table 13: Diagnosed Incidence of AP by Etiology in Germany (2017-2030)

Table 14: Diagnosed Incidence of AP by Severity in Germany (2017-2030)

Table 15: Diagnosed Incidence of AP by Gender in Germany (2017-2030)

Table 16: Recurrent AP Cases in Germany (2017-2030)

Table 17: Total Diagnosed Incident Cases of AP in France (2017-2030)

Table 18: Diagnosed Incidence of AP by Etiology in France (2017-2030)

Table 19: Diagnosed Incidence of AP by Severity in France (2017-2030)

Table 20: Diagnosed Incidence of AP by Gender in France (2017-2030)

Table 21: Recurrent AP Cases in France (2017-2030)

Table 22: Total Diagnosed Incident Cases of AP in Italy (2017-2030)

Table 23: Diagnosed Incidence of AP by Etiology in Italy (2017-2030)

Table 24: Diagnosed Incidence of AP by Severity in Italy (2017-2030)

Table 25: Diagnosed Incidence of AP by Gender in Italy (2017-2030)

Table 26: Recurrent AP Cases in Italy (2017-2030)

Table 27: Total Diagnosed Incident Cases of AP in Spain (2017-2030)

Table 28: Diagnosed Incidence of AP by Etiology in Spain (2017-2030)

Table 29: Diagnosed Incidence of AP by Severity in Spain (2017-2030)

Table 30: Diagnosed Incidence of AP by Gender in Spain (2017-2030)

Table 31: Recurrent AP Cases in Spain (2017-2030)

Table 32: Total Diagnosed Incident Cases of AP in the United Kingdom (2017-2030)

Table 33: Diagnosed Incidence of AP by Etiology in the United Kingdom (2017-2030)

Table 34: Diagnosed Incidence of AP by Severity in the United Kingdom (2017-2030)

Table 35: Diagnosed Incidence of AP by Gender in the United Kingdom (2017-2030)

Table 36: Recurrent AP Cases in the United Kingdom (2017-2030)

Table 37: Total Diagnosed Incident Cases of AP in Japan (2017-2030)

Table 38: Diagnosed Incidence of AP by Etiology in Japan (2017-2030)

Table 39: Diagnosed Incidence of AP by Severity in Japan (2017-2030)

Table 40: Diagnosed Incidence of AP by Gender in Japan (2017-2030)

Table 41: Recurrent AP Cases in Japan (2017-2030)

Table 42: Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015

Table 43: Auxora, Clinical Trial Description, 2020

Table 44: 7 Major Market Size of Acute Pancreatitis in USD Million (2017-2030)

Table 45: United States Market Size of Acute Pancreatitis in USD Million (2017-2030)

Table 46:  The US Market Size of Acute Pancreatitis by Therapies in USD Million (2017-2030)

Table 47: Germany Market Size of Acute Pancreatitis in USD Million (2017-2030)

Table 48:  Germany Market Size of Acute Pancreatitis by Therapies in USD Million (2017-2030)

Table 49: France Market Size of Acute Pancreatitis in USD Million (2017-2030)

Table 50:  France Market Size of Acute Pancreatitis by Therapies in USD Million (2017-2030)

Table 51: Italy Market Size of Acute Pancreatitis in USD Million (2017-2030)

Table 52:  Italy Market Size of Acute Pancreatitis by Therapies in USD Million (2017-2030)

Table 53: Spain Market Size of Acute Pancreatitis in USD Million (2017-2030)

Table 54: Spain Market Size of Acute Pancreatitis by Therapies in USD Million (2017-2030)

Table 55: United Kingdom Market Size of Acute Pancreatitis in USD Million (2017-2030)

Table 56: The UK Market Size of Acute Pancreatitis by Therapies in USD Million (2017-2030)

Table 57: Japan Market Size of Acute Pancreatitis in USD Million (2017-2030)

Table 58: Japan Market Size of Acute Pancreatitis by Therapies in USD Million (2017-2030)

List of Figures

Figure 1: Activation of digestive enzymes within the acinar cell leads to pathological changes.

Figure 2: Indications for Laboratory and Radiologic Testing in Pancreatitis

Figure 3: Signs and Tests for the Diagnosis of Pancreatitis

Figure 4: Diagnosed Incident Population of Acute Pancreatitis in 7MM (2017-2030)

Figure 5: Total Diagnosed Incident Cases of AP in the United States (2017-2030)

Figure 6: Diagnosed Incidence of AP by Etiology in the US (2017-2030)

Figure 7: Diagnosed Incidence of AP by Severity in the United States (2017-2030)

Figure 8: Diagnosed Incidence of AP by Gender in the United States (2017-2030)

Figure 9: Recurrent AP Cases in the United States (2017-2030)

Figure 10: Total Diagnosed Incident Cases of AP in Germany (2017-2030)

Figure 11: Diagnosed Incidence of AP by Etiology in Germany (2017-2030)

Figure 12: Diagnosed Incidence of AP by Severity in Germany (2017-2030)

Figure 13: Diagnosed Incidence of AP by Gender in Germany (2017-2030)

Figure 14: Recurrent AP Cases in Germany (2017-2030)

Figure 15: Total Diagnosed Incident Cases of AP in France (2017-2030)

Figure 16: Diagnosed Incidence of AP by Etiology in France (2017-2030)

Figure 17: Diagnosed Incidence of AP by Severity in France (2017-2030)

Figure 18: Diagnosed Incidence of AP by Gender in France (2017-2030)

Figure 19: Recurrent AP Cases in France (2017-2030)

Figure 20: Total Diagnosed Incident Cases of AP in Italy (2017-2030)

Figure 21: Diagnosed Incidence of AP by Etiology in Italy (2017-2030)

Figure 22: Diagnosed Incidence of AP by Severity in Italy (2017-2030)

Figure 23: Diagnosed Incidence of AP by Gender in Italy (2017-2030)

Figure 24: Recurrent AP Cases in Italy (2017-2030)

Figure 25: Total Diagnosed Incident Cases of AP in Spain (2017-2030)

Figure 26: Diagnosed Incidence of AP by Etiology in Spain (2017-2030)

Figure 27: Diagnosed Incidence of AP by Severity in Spain (2017-2030)

Figure 28: Diagnosed Incidence of AP by Gender in Spain (2017-2030)

Figure 29: Recurrent AP Cases in Spain (2017-2030)

Figure 30: Total Diagnosed Incident Cases of AP in the UK (2017-2030)

Figure 31: Diagnosed Incidence of AP by Etiology in the UK (2017-2030)

Figure 32: Diagnosed Incidence of AP by Severity in the UK (2017-2030)

Figure 33: Diagnosed Incidence of AP by Gender in the UK (2017-2030)

Figure 34: Recurrent AP Cases in the UK (2017-2030)

Figure 35: Total Diagnosed Incident Cases of AP in Japan (2017-2030)

Figure 36: Diagnosed Incidence of AP by Etiology in Japan (2017-2030)

Figure 37: Diagnosed Incidence of AP by Severity in Japan (2017-2030)

Figure 38: Diagnosed Incidence of AP by Gender in Japan (2017-2030)

Figure 39: Recurrent AP Cases in Japan (2017-2030)

Figure 40: Unmet Needs

Figure 41: 7 Major Market Size of Acute Pancreatitis in USD Million (2017-2030)

Figure 42: Market Size of Acute Pancreatitis in the United States, USD Million (2017-2030)

Figure 43: The US Market Size of Acute Pancreatitis by Therapies in USD Million (2017-2030)

Figure 44: Market Size of Acute Pancreatitis in Germany, USD Million (2017-2030)

Figure 45: Germany Market Size of Acute Pancreatitis by Therapies in USD Million (2017-2030)

Figure 46: Market Size of Acute Pancreatitis in France, USD Million (2017-2030)

Figure 47: France Market Size of Acute Pancreatitis by Therapies in USD Million (2017-2030)

Figure 48: Market Size of Acute Pancreatitis in Italy, USD Million (2017-2030)

Figure 49: Italy Market Size of Acute Pancreatitis by Therapies in USD Million (2017-2030)

Figure 50: Market Size of Acute Pancreatitis in Spain, USD Million (2017-2030)

Figure 51: Spain Market Size of Acute Pancreatitis by Therapies in USD Million (2017-2030)

Figure 52: Market Size of Acute Pancreatitis in the United Kingdom, USD Million (2017-2030)

Figure 53: The UK Market Size of Acute Pancreatitis by Therapies in USD Million (2017-2030)

Figure 54: Market Size of Acute Pancreatitis in Japan, USD Million (2017-2030)

Figure 55: Japan Market Size of Acute Pancreatitis by Therapies in USD Million (2017-2030)

Figure 56: Market Drivers

Figure 57: Market Barriers

CalciMedica, Inc.

  • Tags:
  • Acute Pancreatitis market
  • Acute Pancreatitis market research
  • Acute Pancreatitis market insight
  • Acute Pancreatitis market trends
  • Acute Pancreatitis market forecast
  • Acute Pancreatitis market share
  • Acute Pancreatitis pipeline drugs
  • Acute Pancreatitis treatment algor...
  • Acute Pancreatitis drugs
  • Acute Pancreatitis sales forecasti...
  • Acute Pancreatitis market size
  • Acute Pancreatitis disease
  • Acute Pancreatitis epidemiology
  • Acute Pancreatitis

Forward to Friend

Need A Quote